TNYA

Insider Trades

Actor	Holding Value	Last Transaction	Amount	Transaction Price	Current Price
Burroughs Amy L.Director $96k120k shares Grant / ExerciseMay 28, 2026 $95.9K120k shares $0.7989 --
Lee JuneDirector $96k120k shares Grant / ExerciseMay 28, 2026 $95.9K120k shares $0.7989 --
Parschauer Karah HerdmanDirector $96k120k shares Grant / ExerciseMay 28, 2026 $95.9K120k shares $0.7989 --
Srivastava DeepakDirector $96k120k shares Grant / ExerciseMay 28, 2026 $95.9K120k shares $0.7989 --
Stehman-Breen CatherineDirector $96k120k shares Grant / ExerciseMay 28, 2026 $95.9K120k shares $0.7989 --
Walsh Jeffrey T.Director $96k120k shares Grant / ExerciseMay 28, 2026 $95.9K120k shares $0.7989 --

News

seekingalpha.comTenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcriptseekingalpha.comJun 5

seekingalpha.comTenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcriptseekingalpha.comJun 3

globenewswire.comTenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptomsglobenewswire.comJun 3

globenewswire.comTenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026globenewswire.comJun 2

globenewswire.comTenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026globenewswire.comMay 29

Trade TNYA

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. is a U.S.-based biotechnology firm focused on unearthing, advancing, and providing novel treatments for various cardiovascular diseases. The company harnesses advanced scientific platforms, including cellular regeneration, gene therapy, and precision medicine, to develop its therapeutic candidates. Among its primary therapeutic initiatives is TN-201, an adeno-associated virus (AAV)-based gene therapy engineered to tackle genetic hypertrophic cardiomyopathy (gHCM) arising from haploinsufficient mutations in the myosin binding protein C3 (MYBPC3) gene. A prominent compound in its pipeline is TN-301, a small molecule histone deacetylase 6 inhibitor (HDAC6i) slated for use in both heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). Tenaya is also progressing TN-401, another AAV-based gene therapy aimed at genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) resulting from specific plakophilin 2 (PKP2) gene anomalies. Further, an AAV gene therapy is under development that seeks to introduce the dwarf open reading frame (DWORF) gene into cardiac tissue to address dilated cardiomyopathy (DCM). Rounding out its innovative portfolio, the 'Reprogramming program' employs an AAV-driven approach for cardiac regeneration, striving to replenish heart cells lost in patients who experience heart failure subsequent to a prior myocardial infarction. Founded in 2016, Tenaya operates from its base in South San Francisco, California.

CEO: Faraz Ali
IPO Date: Jul 30, 2021

Market Data

Open: $0.7008
High: $0.735
Low: $0.675
Volume: 2.7M
52W High: $2.35
52W Low: $0.532

Valuation

Market Cap: $118M
Enterprise Value: $48M

Financials

Free Cash Flow: $-69M
Revenue: $0
Net Income: $-91M
Cash: $101M
Debt: $11M

Events

EarningsAug 5

EPS est. -0.08